Evidence map›Paper›PMID 42031536›Full record

ArticleJournal of medical genetics2026

Ryan N Baugher, Stephanie D Mellott, Kristen M Pike, Todd B Young, Heidi E Lawhorn, Stephen M Hewitt

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ryan N BaugherCLIA Molecular Diagnostics Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA baugherrn@mail.nih.gov.ORCID http://orcid.org/0000-0002-1658-7569
Stephanie D MellottCLIA Molecular Diagnostics Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
Kristen M PikeCLIA Molecular Diagnostics Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
Todd B YoungCLIA Molecular Diagnostics Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
Heidi E LawhornCLIA Molecular Diagnostics Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
Stephen M HewittLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
NIH HHS 75N91019D00024
6 · The paper itself

Abstract

von Hippel-Lindau (VHL) is an autosomal-dominant tumour susceptibility disorder associated with pathogenic germline variants in the

Indexed as

Alu ElementsChromosome Inversionvon Hippel-Lindau DiseaseVon Hippel-Lindau Tumor Suppressor ProteinFemaleGenetic TestingGerm-Line MutationHumansMalePolymerase Chain ReactionVHL protein, humanVon Hippel-Lindau Tumor Suppressor ProteinClinical Laboratory TechniquesGene RearrangementGenetic Diseases, InbornGeneticsHuman Genetics

Identifiers

PMID42031536
PMCPMC13416925

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.